Nature Reviews Drug Discovery：中国肿瘤新药发展概述

There has never been a more exciting pharmaceutical era in China, with the R&D emphasis shifting from generic to innovative drugs. Oncology has been at the forefront of this transition. Indeed, 12 out of 44 of the new cancer drugs approved in China in between 2018 and August 2020 were discovered in China. Although most were me-too drugs from established drug classes, first-in-class candidates are also emerging.

Here, we overview the landscape of domestic oncology drug pipelines in China, with the aim of providing insights on the evolution of the pharmaceutical ecosystem and R&D trends. For details of the data and analysis as well as additional figures, see the Supplementary Information.

As of January 2020, there were 821 investigational anticancer drug candidates in China, including 404 me-too and 359 first-in-class agents.

全文请参考

https://www.nature.com/nrd/；